Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Menorrhagia
100%
Levonorgestrel-releasing Intrauterine System (LNG-IUS)
91%
Medical Treatment
75%
Randomized Controlled Trial
52%
Primary Care
50%
Abnormal Uterine Bleeding
36%
Cost-effectiveness
26%
Medical Therapy
26%
Economic Evaluation
26%
Levonorgestrel IUS
23%
Randomized Pragmatic Trial
23%
Pharmaceutical Therapy
23%
Willingness to Pay
23%
Cost-benefit Analysis
23%
Quality-adjusted Life Years
18%
Surgical Intervention
12%
EQ-5D
11%
SF-6D
11%
Multicenter Randomized Trial
10%
Sexual Behavior
10%
Confidence Interval
8%
Multi-attribute
8%
Attribute Scale
8%
Primary Care Providers
7%
Oral Treatment
7%
Welfarist
7%
Treatment as Usual
6%
Serious Adverse Events
6%
Progesterone
6%
Family Life
6%
Working Life
6%
Social Life
6%
Mefenamic Acid
6%
General Quality of Life
6%
Cost-effective Treatment
5%
Quality of Life
5%
Net Present Value
5%
Preliminary Cost
5%
Nursing and Health Professions
Menorrhagia
95%
Levonorgestrel Releasing Intrauterine System
70%
Combination Therapy
69%
Primary Medical Care
55%
Levonorgestrel
29%
Cost Effectiveness Analysis
27%
Quality of Life
27%
Quality Adjusted Life Year
26%
Economic Evaluation
26%
Cost Benefit Analysis
23%
Drug Therapy
23%
Confidence Interval
8%
Randomization
6%
Mefenamic Acid
5%
Adverse Event
5%
Progesterone
5%
Health Care
5%
Medicine and Dentistry
Primary Health Care
47%
Levonorgestrel
47%
Menorrhagia
47%
Combination Therapy
43%
Randomized Controlled Trial
27%
Cost-Effectiveness Analysis
23%
Quality of Life
15%
Quality Adjusted Life Year
8%
Health Care Cost
6%
Mefenamic Acid
5%
Family Life
5%
Adverse Event
5%
Social Participation
5%
Progesterone
5%